Method for inhibiting inflammation with an antibody that binds the 5C8 protein
| Title: | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
|---|---|
| Patent Number: | 7,070,777 |
| Publication Date: | July 04, 2006 |
| Appl. No: | 08/476649 |
| Application Filed: | June 07, 1995 |
| Abstract: | This invention provides for methods of inhibiting inflammation with antibodies that bind the 5c8 protein. |
| Inventors: | Lederman, Seth (New York, NY, US); Chess, Leonard (Scarsdale, NY, US); Yellin, Michael J. (Riverdale, NY, US) |
| Assignees: | The Trustees of Columbia University in the City of New York (New York, NY, US) |
| Claim: | 1. A method for inhibiting inflammation in a human subject which comprises administering to the human subject an effective amount of a pharmaceutical composition which comprises a monoclonal antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916; and a pharmaceutically acceptable carrier. |
| Claim: | 2. The method of claim 1 , wherein the subject is suffering from rheumatoid arthritis, osteoarthritis, psoriasis or contact dermatitis. |
| Claim: | 3. The method of claim 1 , wherein the monoclonal antibody is a chimeric antibody. |
| Claim: | 4. The method of claim 1 , wherein the monoclonal antibody is a humanized antibody. |
| Claim: | 5. The method of claim 1 , wherein the monoclonal antibody is monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. |
| Claim: | 6. The method of claim 1 , wherein the carrier is selected from the group consisting of a buffered saline, a physiological saline, water, and a water/oil emulsion. |
| Claim: | 7. The method of claim 1 , wherein the administration comprises intravenous, intraperitoneal or intramuscular administration. |
| Claim: | 8. The method of claim 1 , wherein the subject is a mouse, a primate or a human. |
| Claim: | 9. The method of claim 1 , wherein the antibody is an antibody which specifically binds to the epitope to which monoclonal antibody 5c8, produced by the hybridoma having ATCC Accession No. HB 10916, binds. |
| Claim: | 10. The method of claim 1 , wherein the monoclonal antibody is a human antibody. |
| Current U.S. Class: | 4241/541 |
| Patent References Cited: | 5102909 April 1992 Veltri et al. 5340829 August 1994 Clark et al. 5474771 December 1995 Lederman et al. 5683693 November 1997 Noelle et al. 5747037 May 1998 Noelle et al. 5833987 November 1998 Noelle et al. 5961974 October 1999 Armitage et al. 5993816 November 1999 Lederman et al. 0555880 August 1993 9007861 July 1990 9308207 April 1993 WO9506480 March 1995 WO9623071 August 1996 WO9830240 July 1998 WO9830241 July 1998 |
| Other References: | Paul (H2 ) Fundamental Immunology 3rd (8). Raven Press p. 242 only 1993. cited by examiner Noelle Immunity 4 : 415-419 (1996). cited by examiner Edgington Biotechnology 11: 998-1000 (1993). cited by examiner Durie et al., J. Clin. Invest. 94: 1333-1338 (1994). cited by examiner Lenz et al., J. Clin Invest. 92: 2587-2596 (1993). cited by examiner Lederman et al. Research in Immunology 145(3) 215-221(1994). cited by examiner Akdis et al. (1997) Eur. J. Immunol. 27:2351-2357. cited by other Bartlett, W.C., et al. (1990). J. Immunol. 145: 3956-3962. cited by other Callard et al. (1993) Imm. Today 14:559-564. cited by other Christadoss, P. and Dauphinee, M.J. (1986) J. Immunol. 136:2437-2440. cited by other Clark, E.A. and Ledbetter, J.A. (1986) Proc. Natl. Acad. Sci. USA 83:4494-4498. cited by other Cosimi A.B. et al (1981) Transplant Proc 13:499-503. cited by other Durie et al. (1994) J. Clin. Invest. 94:1333-38. cited by other Edgington et al. (1993) Biotech. 11:998-1000. cited by other Freeman, G. J., et al.(1991). J. Exp. Med.174:625-631. cited by other Gascan H. et al. (1991) J. Immunol 147:8-13. cited by other Goldberg D. et al. (1991) J. Autoimmun. 4:617-630. cited by other Gordon J. et al. (1988) J. Immunol. 140:1425-1430. cited by other Hafler D.A. (1988) J. Immunol 141:131-138. cited by other Reiter C. et al. (1991) Arthiritis & Rheum. 34:525-36. cited by other Satoh J. et al. (1988) J. Neuroimmunol.18:105-116. cited by other Schwarz R.H. et al. (1990) Sci. 248:1349-1356. cited by other Shizuru J.A. et al. (1988) Sci. 240659-662. cited by other Snow E. C . et al. (1989) Fed. Am. Soc. for Exp. Bio. 73rd meeting Abs No.4267. cited by other Sriram S. et al. (1986) J. Immunol. 136:4464-69. cited by other Stull S.J. at al. (1988)Cell Immunol. 117:188-98. cited by other Traugott U. (1983) Science 219:308-310. cited by other Traugott U. (1983) J. Neuroimmunol. 4:201-21. cited by other Valent P. et al. (1990) Int. Arch. Allergy. Appl. Immunol. 91:198-203. cited by other van Seventer G.A. et al. (1990) J. Immunol. 144:4579-4586. cited by other Waldmann H. et al. (1989) Ann. Rev. Immunol. 7:407-444. cited by other Waldor M.K. et al (1985) Sci. 227:415-17. cited by other Williams I.R. et al. (1990) J. Immunol. 145:85-93. cited by other Wofsy, D., et al. (1985). J. Immunol. 134:852-857. cited by other Wofsy, D. and Seaman, W.E. (1985). (S.H. Pincus, et al. eds.), pp. 187-195. cited by other Wofsy, D. and Seaman, W.E. (1985). J. Exp.Med. 161:378-391. cited by other Wofsy, D. and Seaman, W.E. (1987). J. Immunol. 138:3247-3253. cited by other Wofsy, D. (1986). J. Immunol. 136:4554-4560. cited by other Wofsy, D. and Carteron, N.L. (1990). Semin. Immunol. 2:419-425. cited by other Young, L.S., et al. (1989) Int. J. Cancer 43:786-794. cited by other Haynes M. K. et al. (1987) Diabetes 36:877-881. cited by other Horneff G. et al. (1991) Arthritis & Rheum. 34:129-140. cited by other Jenkins M.K. et al. (1987) J. Exp. Med. 165:302-319. cited by other Junghans R.P. (1990) Cancer Res. 50:1495-1502. cited by other Kennedy M.K .(1987) J. Neuroimmunol. 16:345-364. cited by other Koike T. (1987) Diabetes 36:539-541. cited by other Kung P.C. et al. (1979) Sci. 206:347-349. cited by other Kung P.C. et al. (1980) Vox. Sang. 39:121-127. cited by other Lederman S. et al. (1994) Res. in Imm. 145(3):215-221. cited by other Lenz et al. (1993) J. Clin. Invest. 92:2587-2596. cited by other Ling N.R. (1987) A.J. Michaels ed p302-35. cited by other Linsley P.S. et al. (1991) J. Exp. Med. 174:561-569. cited by other Madec A.M. et al. (1996) J. Immunol. 156:3541-3549. cited by other Marshall L. S. et al. (1990) Res. Immunol. 141:412-417. cited by other Noelle R.J. et al (1996) Immunity 4:415-19. cited by other Noelle R. (1990) Imm.Today 11(10):361-68. cited by other Paul (Ed) Fund. Imm., Third Edition Raven Press p242 (1993). cited by other Pisetsky D.S. (1985) in Pincus S.H. et al eds. p171-76. cited by other Potocnik A.J. et al. (1990) Scand. J. Immol. 31:213-224. cited by other Ranges G.E et al. (1985) J. Exp. Med. 162:1105-1110. cited by other Reinherz E.L. et al. (1979) J. Exp. Med. 150:1472-1482. cited by other R.J. Armitage, et al., Nature (1992) 357:80-82. cited by other P. Lane, et al., Eur. J. Immunol. (1992) 22:2573-2578. cited by other L.S. Marshall and R.J. Noelle, FASEB J. (1991) 5(4):A608; Abstract No. 1379. cited by other R.J. Noelle, et al., Proc. Natl. Acad. Sci USA (1992) 89:6550-6554. cited by other R.J. Noelle, et al., Immunol. Today (1992) 13(11):431-433. cited by other R.J. Noelle and E.C. Snow, FASEB J. (1991) 5(13):2770-2776. cited by other R. Noelle and E.C. Snow, Current Opinion in Immunology (1992) 333-337. cited by other R.J. Noelle, et al. in Mechanisms of Lymphocyte Activation and Immune Regulation IV: Cellular Communications, S. Gupta and T.A. Waldmann, eds. (Plenum, New York 1992) 131-137. cited by other Waldmann, T.A., Science (1991) 252:1657-1662. cited by other Cunningham, C., et al., TIBTECH (1992) vol. 10. cited by other Rogozinski, et al., J. Immunol. (1984) 132:735-739. cited by other Dillman, R.O., Annals Int. Med. (1989) 111:592-603. cited by other Weiss, et al., Adv. Immunol. (1987) 41:1-38. cited by other Harris, W., et al., TIBTECH (1993) 11:42-44. cited by other Lederman, et al., J. Exp. Med. (1992) 175:1091-1101. cited by other Joliffe, L.K., Intern. Rev. Immunol. (1993) 10:241-250. cited by other Borrebaeck, C.A.K., et al., Immunol. Today (1993) 14:477-482. cited by other Kahan, B., Current Opin. Immunol. (1992) 4:553-560. cited by other Tueveson, G., et al., Immunol. Rev. (1993) Issue No. 136:99-109. cited by other Emery, S.C., et al., Exp. Opin. Invest. Drugs (1994) 3:241-251. cited by other Winter, G., et al., TIPS (1993) 14:139-143. cited by other Borst, J., et al., Eur. J. Immunol. (1989) 19:357-364. cited by other Brian, A., Proc. Natl. Acad. Sci. USA (1988) 85:564-568. cited by other Crow, M.K., et al., Cell. Immunol. (1989) 121:99-112. cited by other Damle, N.K., et al., Eur. J. Immunol. (1991) 21:1277-1282. cited by other Hirohata, S., et al. J. Immunol. (1988) 140(11):3736-3744. cited by other Hodgkin, P.D., et al., J. Immunol. (1990) 145:2025-2034. cited by other Kubota, E., et al., Immunol. (1991) 72:40-47. cited by other Noelle, R.J., et al., J. Immunol. (1989) 143(6):1807-1814. cited by other Noelle, R.J., et al., J. Immunol. (1991) 146(4):1118-1124. cited by other Rabin, E.M., et al., Proc. Natl. Acad. Sci. USA (1985) 82:2935-2939. cited by other Reinherz, E.L., et al., J. Exp. Med. (1979) 150:1472-1482. cited by other Sanders, V.M., et al., J. Immunol. (1986) 137(8):2395-2404. cited by other Sekita, K., et al., Eur. J. Immunol. (1988) 18:1405-1410. cited by other Smith, S.H., et al., Immunol. (1986) 58:63-70. cited by other Tohma, S., Hirohata, S., and Lipsky, P.E., J. Immunol. (1991) 146(2):492-499. cited by other Tohma, S., and Lipsky, P.E., J. Immunol. (1991) 146(8):2544-2552. cited by other Torimoto, Y., et al., J. Immunol. (1991) 146(7):2176-2184; and. cited by other Lauzon, G.J., et al., Molecular Immunology (1988) 25(9):829-841. cited by other G. Inghirami, et al., Blood (1994) 84:866-872. cited by other J. Hakimi, et al., J. Immunol. (1991) 147:1352-1359. cited by other C. Queen, et al., Proc. Natl. Acad. Sci. USA (1989) 86:10029-10033. cited by other Press Release from Biogen, Inc., dated Oct. 21, 1999, “Biogen Says It Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody” (Exhibit B). cited by other Press Release from Biogen, Inc., dated Nov. 2, 1999, “Biogen Says It Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody” (Exhibit C). cited by other Press Release from IDEC Pharmaceuticals, Inc., dated Apr. 20, 2000, “First Quarter 2000 Results” (see section entitled “IDEC-131 (anti-CD40L)”) (Exhibit D). cited by other BioWorld Today, Oct. 25, 1999, “Biogen Halts Trials of Antova After Reporting Adverse Events” (Exhibit E). cited by other Gray, D. et al. (1994) J. Exp. Med. 180:141-155 (Exhibit F). cited by other Stüber, E. et al. (1996) J. Exp. Med. 183:693-698 (Exhibit G). cited by other Jaffar, Z. H. et al. (1999) J. of Immunology, 6283-6291 (Exhibit H). cited by other Akdis, C. A. et al. (1997) Eur. J. Immunology 27:2351-2357 (Exhibit I). cited by other Buhlmann J Clin Immunol. 16:83-89 (1996). cited by examiner Resetkova et al. Thyroid 6: 267-273 (1996). cited by examiner Stuber et al. J. Exp. Med. 183: 693-698 (1996). cited by examiner Gray et al. J. Exp Med. 180: 141-155 (1994). cited by examiner Biacone et al. Kidney Intl. 48: 458-468 (1995). cited by examiner Larsen Transplantation 61: 4-9 (1996). cited by examiner Datta Arthritis and Rheumatism. cited by examiner Strom T.B. et al. 1989, “Toward More Selective Therapies to Block Undesired Immune Responses”, Kidney International 35(4):1026-1033. (Exhibit 1). cited by other Yellin M.J. et al. 1991, “A Human CD4 Negative T-Cell Leukemia Cell Subclone with Contact-Dependent Helper Function”, Journal of Immunology 147(10): 3389-3395. (Exhibit 2). cited by other Lederman S. et al. 1992, “Anti-CD40 Monoclonal Antibody Blocks the Contact Dependent T Helper Signal Medicated by 5c8 Antigen”, Clinical Research 40(2) :154A. (Exhibit 3). cited by other |
| Primary Examiner: | Gambel, Phillip |
| Attorney, Agent or Firm: | White, John P. Cooper & Dunham LLP |
| Accession Number: | edspgr.07070777 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|